Breaking News Instant updates and real-time market news.

SLM

Sallie Mae

$10.09

0.095 (0.95%)

, WFC

Wells Fargo

$46.50

0.18 (0.39%)

04:55
05/15/19
05/15
04:55
05/15/19
04:55

Barclays to hold a conference

Americas Select Franchise Conference will be held in London, England on May 14-15.

SLM

Sallie Mae

$10.09

0.095 (0.95%)

WFC

Wells Fargo

$46.50

0.18 (0.39%)

INFO

IHS Markit

$56.15

1.49 (2.73%)

MCO

Moody's

$186.79

2.96 (1.61%)

BBT

BB&T

$48.03

0.215 (0.45%)

TRU

TransUnion

$64.20

0.48 (0.75%)

FDS

FactSet

$276.80

4.56 (1.68%)

CFG

Citizens Financial

$34.91

0.39 (1.13%)

MTZ

MasTec

$48.38

0.65 (1.36%)

USB

U.S. Bancorp

$51.06

0.25 (0.49%)

NDAQ

Nasdaq

$91.10

0.2 (0.22%)

SPGI

S&P Global

$211.77

3.09 (1.48%)

RF

Regions Financial

$14.54

0.2 (1.39%)

MTB

M&T Bank

$162.66

1.03 (0.64%)

BK

BNY Mellon

$47.00

-0.16 (-0.34%)

CGC

Canopy Growth

$45.28

1.555 (3.56%)

  • 15

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 29

    May

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 13

    Jul

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 12

    Oct

  • 13

    Nov

SLM Sallie Mae
$10.09

0.095 (0.95%)

12/21/18
WEDB
12/21/18
NO CHANGE
Target $275
WEDB
Outperform
Apple, EA, Nordstrom, SLM removed from Wedbush's Best Ideas List
02/21/19
WEDB
02/21/19
NO CHANGE
WEDB
Sallie Mae added to Best Ideas List at Wedbush
Wedbush added Sallie Mae to the Best Ideas List, as the firm believes that it will be able to keep EPS growing at 12%-15% per year over the next three years, continue to expand on its return of capital measures, and address the opportunities in its core, undergraduate, in school market and its graduate school lending initiative.
01/25/19
BMOC
01/25/19
UPGRADE
BMOC
Outperform
Sallie Mae upgraded to Outperform from Market Perform at BMO Capital
01/25/19
BMOC
01/25/19
UPGRADE
Target $16
BMOC
Outperform
Sallie Mae upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst James Fotheringham upgraded Sallie Mae to Outperform and raised his price target to $16 from $15. The analyst cites the company's big Q4 earnings beat, "encouraging guidance", and the start of dividends and buybacks, adding that its valuation of 7.4-times two-year forward earnings multiple is also attractive. Fotheringham further states that Sallie Mae's dominant market position is "increasing and secure, despite new entrants."
WFC Wells Fargo
$46.50

0.18 (0.39%)

04/15/19
DBAB
04/15/19
NO CHANGE
Target $48
DBAB
Hold
Wells Fargo price target lowered to $48 from $54 at Deutsche Bank
Deutsche Bank analyst Matt O'Connor lowered his price target for Wells Fargo to $48 from $54 citing management's reduced outlook for net interest income and fewer share buybacks. The analyst keeps a Hold rating on Wells Fargo.
04/15/19
04/15/19
DOWNGRADE

Neutral
Wells Fargo downgraded to Neutral at BofA/Merrill
As previously reported, BofA/Merrill downgraded Wells Fargo to Neutral from Buy and cut its price target to $50 from $57. Analyst Erika Najarian said there is a further deterioration in earning visibility and shares lack an upside catalysts until a new CEO is announced.
04/15/19
04/15/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CVS Health (CVS) downgraded to Perform from Outperform at Oppenheimer with analyst Michael Wiederhorn saying he views it as more of a long-term opportunity given the potential timeline to execute on its strategy and the near-term legacy business challenges. 2. Infosys (INFY) downgraded to Hold from Buy at Deutsche Bank and Investec, to Reduce from Neutral at Nomura Instinet, to Underperform from Neutral at Credit Suisse, to Equal Weight from Overweight at Morgan Stanley, and to Neutral from Buy at Citi and BofA/Merrill. 3. Celanese (CE) downgraded to Hold from Buy at Deutsche Bank with analyst David Begleiter saying the company's leadership transition creates uncertainty. 4. Alliance Data (ADS) downgraded to Underweight from Equal Weight at Stephens and to Market Perform from Outperform at BMO Capital. 5. Wells Fargo (WFC) downgraded to Neutral from Conviction Buy at Goldman Sachs, to In Line from Outperform at Evercore ISI, and to Neutral from Buy at BofA/Merrill and Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/15/19
GSCO
04/15/19
DOWNGRADE
Target $48
GSCO
Neutral
Goldman downgrades Wells Fargo to Neutral, takes off Conviction list
Goldman Sachs analyst Richard Ramsden on Friday night downgraded Wells Fargo to Neutral from Buy and removed the shares from his firm's Americas Conviction List. The recent departure of Tim Sloan and questions over the time it will take to find a replacement, coupled with commentary on the Q1 earnings call around weaker than expected net interest income growth for 2019, has increased focus on Wells Fargo's ability to meet near term and longer term financial targets, Ramsden tells investors in a research note. The analyst expects the company's medium term operating leverage potential to be impacted by weaker net interest income growth. He cut his price target for the shares to $48 from $58.
INFO IHS Markit
$56.15

1.49 (2.73%)

03/20/19
PIPR
03/20/19
NO CHANGE
Target $61
PIPR
Overweight
IHS Markit Q1 to confirm 'steady as she goes' thesis, says Piper Jaffray
Piper Jaffray analyst Peter Appert says IHS Markit is his "favorite kind of investment story, with consistent execution driving potential for compound returns" that match his long-term forecast of low-teens earnings growth. He expects the company's Q1 results to reinforce his "steady as she goes" thesis, with mid-single digit organic revenue growth and positive underlying margin trends. The analyst keeps an Overweight rating on the shares with a $61 price target.
04/02/19
PIPR
04/02/19
NO CHANGE
Target $64
PIPR
Overweight
IHS Markit price target raised to $64 from $61 at Piper Jaffray
Piper Jaffray analyst Peter Appert raised his price target for IHS Markit to $64 from $61 following a series of meetings with CEO Lance Uggla and CFO Todd Hyatt. Uggla expressed a high level of confidence in the sustainability of mid-single digit organic revenue growth with 100 basis points per year of margin improvement, Appert tells investors in a research note. Further, the analyst thinks the company's Q2 is "starting on a healthy note." He has confidence in IHS Markit's near-term growth outlook and enthusiasm for its secular growth story. Appert reiterates an Overweight rating on the shares.
03/27/19
BMOC
03/27/19
NO CHANGE
Target $59
BMOC
Outperform
IHS Markit Q1 organic growth stable, says BMO Capital
BMO Capital analyst Jeffrey Silber kept his Outperform rating and $59 price target on IHS Markit after its Q1 earnings beat, saying the company's organic growth was "stable sequentially, with improvements in Resources and Financial Services". The analyst also notes that the management affirmed its FY19 guidance in spite of some "bumps", that included "Ipreo lower equity issuance and a CMS decline from contract renewal uncertainty." Silber warns that the stock price could see some weakness but also maintains his view of IHS Markit as a "strong long-term story".
03/27/19
RHCO
03/27/19
NO CHANGE
Target $62
RHCO
Buy
IHS Markit offers 'strong risk-reward', says SunTrust
SunTrust analyst Andrew Jeffrey kept his Buy rating and $62 price target on IHS Markit after its "mixed" Q1 results, saying the company should deliver "mid-single % organic rev growth and about 100bps of normalized EBITDA margin expansion this year" in spite of its weak CMS results and soft Ipreo commentary. The analyst believes that this performance, along with "disciplined capital allocation", should support IHS Markit valuation, adding that IHS Markit organic revenue growth in Q1 was above average at 8% and should remain in high-single-digits for the year as it benefits from "a robust Consumer, Manufacturer and Dealer ecosystem".
MCO Moody's
$186.79

2.96 (1.61%)

02/19/19
BMOC
02/19/19
NO CHANGE
Target $172
BMOC
Market Perform
Moody's price target raised to $172 from $164 at BMO Capital
BMO Capital analyst Jeffrey Silber raised his price target on Moody's to $172, saying the miss in its Q4 earnings came from the MIS segment decline that was offset by strong expense efficiencies and margin expansion. The analyst also cites the company's better than expected guidance "driven by new products to offset slower MIS trends", accelerating buybacks, and cost controls. Silber keeps his Market Perform rating on Moody's, noting that while its "entry into private company information should diversify the business", it remains "mostly exposed to debt issuance trends."
04/05/19
PIPR
04/05/19
NO CHANGE
Target $242
PIPR
Overweight
Piper boosts S&P Global price target to $242, Moody's target to $205
Piper Jaffray analyst Peter Appert raised his price target for Overeight-rated S&P Global (SPGI) to $242 from $220 and for Neutral-rated Moody's (MCO) to $205 from $178. Debt issuance in Q1 was a "mixed bag," with "impressive" strength in investment grade and high yield issuance balanced by weaker performance in the loan and structured finance categories, Appert tells investors in a research note. The analyst's increased price targets reflect confidence in the secular growth story and higher multiples in the peer group. He remains a fan of the rating agency business model with a "modest preference" for S&P Global over Moody's given its "more diversified business mix and greater margin upside."
04/25/19
CANT
04/25/19
NO CHANGE
Target $192
CANT
Neutral
Moody's price target raised to $192 from $168 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi raised his price target for Moody's to $192 from $168 after the company reported Q1 results above consensus but keeps a Neutral rating on the name. The analyst remains cautious about the "volatile" issuance market.
03/20/19
BMOC
03/20/19
NO CHANGE
Target $182
BMOC
Market Perform
Moody's price target raised to $182 from $172 at BMO Capital
BMO Capital analyst Jeffrey Silber raised his price target on Moody's to $182 after meeting with its management and discussing the company strategy. The analyst says that while he has gained greater appreciation for the company's non-rating business - Moody's Analytics - following the meetings, he is still keeps his Market Perform rating on the stock given the "sluggish near-term debt issuance" environment.
BBT BB&T
$48.03

0.215 (0.45%)

03/26/19
03/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Strong Buy from Market Perform at Raymond James , to Hold from Sell at Loop Capital, and to Sector Weight from Underweight at KeyBanc. 2. BB&T (BBT) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying after meeting with CEO of SunTrust (STI), he remains positive on the merger and the combined stock. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at William Blair with analyst Y. Katherine Xu citing expectations that the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. 4. Allegiant Travel (ALGT) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio citing her meetings with its management last week. 5. TransAlta (TAC) upgraded to Buy from Hold at TD Securities with analyst John Mould saying Brookfield Renewable Partners (BEP) $750M investment in TransAlta improves the company's financial flexibility, accelerates its ability to return capital to shareholders and advance the coal-to-gas conversion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/19
RAJA
04/04/19
DOWNGRADE
RAJA
Market Perform
BB&T downgraded to Market Perform from Outperform at Raymond James
04/04/19
04/04/19
UPGRADE
Target $44

Strong Buy
Synovus upgraded to Strong Buy at Raymond James
As previously reported, Raymond James analyst David Lon upgraded Synovus (SNV) to Strong Buy from Outperform, with a $44 price target. The analyst cited the recent pullback in the stock and what he sees as an outsized opportunity for market share gain stemming from the recently announced BB&T (BBT)-SunTrust (STI) mega merger.
04/04/19
RAJA
04/04/19
DOWNGRADE
RAJA
Market Perform
BB&T downgraded to Market Perform on near-term noise at Raymond James
As previously reported, Raymond James analyst David Lon downgraded BB&T (BBT) to Market Perform from Outperform and reducing his EPS estimates. The analyst cited the nearer-term noise surrounding its merger with SunTrust (STI) and his view that BB&T shares are unlikely to outperform until there is greater clarity on when the deal will actually close and its ability to retain key talent with the combined company's footprint. Moreover, larger acquirer stock prices generally haven't reacted favorably over the past few years, he contends.
TRU TransUnion
$64.20

0.48 (0.75%)

04/24/19
BARD
04/24/19
NO CHANGE
Target $78
BARD
Outperform
TransUnion still a top idea despite 'modestly disappointing' Q1, says Baird
Baird analyst Jeffrey Meuler said TransUnion's Q1 results were "modestly disappointing, but not thesis changing" and the stock remains his top information solutions idea given that he expects accelerating growth in the near-term and sustained strong growth at attractive economics over the long-term. Despite the Q1 results, strong bookings trends, improved trends in shorter-cycle/batch revenue in March/April relative to January/February and a more favorable mortgage market outlook are among the factors he points to that give him confidence in a reacceleration. Meuler keeps an Outperform rating on TransUnion shares and raised his price target on the stock to $78 from $75.
03/15/19
EXAN
03/15/19
INITIATION
Target $66
EXAN
Neutral
TransUnion initiated with a Neutral at Exane BNP Paribas
Exane BNP Paribas initiated TransUnion with a Neutral and $66 price target.
12/07/18
FBCO
12/07/18
INITIATION
Target $70
FBCO
Neutral
TransUnion initiated with a Neutral at Credit Suisse
Target $70.
11/30/18
LEHM
11/30/18
UPGRADE
Target $225
LEHM
Overweight
Barclays upgrades Fair Isaac to Overweight following recent pullback
Barclays analyst Manav Patnaik upgraded Fair Isaac (FICO) to Overweight from Equal Weight and raised his price target for the shares to $225 from $200. The analyst says his constructive view on the stock comes on the back of the recent pullback as well as his appreciation of the company's evolution as a Software name. Patnaik prefers shares of Fair Isaac and TransUnion (TRU) over Equifax (EFX) and Dun & Bradstreet (DNB).
FDS FactSet
$276.80

4.56 (1.68%)

03/27/19
DADA
03/27/19
NO CHANGE
Target $214
DADA
Neutral
FactSet price target raised to $214 from $206 at DA Davidson
DA Davidson analyst Peter Heckmann raised his price target on FactSet to $214 after its "solid" Q2 results and upward adjustment to the midpoint of its FY19 earnings guidance. The analyst is citing the management's increased focus on operating expenses and favorable FX changes, but also points to the company's constant-currency organic revenue growth of 5.7% coming on the lower end of the recent 5.5%-6.5% range. Heckmann is keeping his Neutral rating on FactSet and contends that its "valuation seems full", even though he still sees the company "well positioned to generate solid growth in revenue and earnings in the intermediate term".
03/27/19
CANT
03/27/19
NO CHANGE
Target $240
CANT
Neutral
FactSet price target raised to $240 from $209 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi raised his price target for FactSet Research to $240 from $209 following the company's Q2 results but maintains a Neutral rating on the name. The analyst sees reduced market volatility and has optimism about FactSet's margin expansion and "faster-than-expected" integration of Merrill Lynch. However, he's looking for a driver for organic growth-rate reacceleration.
03/27/19
DBAB
03/27/19
NO CHANGE
Target $245
DBAB
Hold
FactSet price target raised to $245 from $217 at Deutsche Bank
Deutsche Bank analyst Ashish Sabadra raised his price target for FactSet Research to $245 from $217 saying the company surprised with a "robust" 180 basis points of margin expansion in Q2. The analyst, however, has questions question about the sustainability of the expansion. Although the company reiterated 100 basis points of margin expansion in fiscal 2019, it was noncommittal for the same growth for 2020, Sabadra tells investors in a post-earnings research note. He keeps a Hold rating on FactSet.
03/27/19
PIPR
03/27/19
NO CHANGE
Target $262
PIPR
Overweight
FactSet price target raised to $262 from $211 at Piper Jaffray
Piper Jaffray analyst Peter Appert raised his price target for FactSet Research to $262 from $211 saying margin upside drove the Q2 earnings beat. Backlog growth suggests FactSet continues to gain market share, Appert tells investors in a research note. The analyst is a fan of the company's business model but views the stock as fairly valued at current levels. As such, he reiterates a Neutral rating on FactSet.
CFG Citizens Financial
$34.91

0.39 (1.13%)

04/04/19
GSCO
04/04/19
DOWNGRADE
Target $84
GSCO
Neutral
Goldman downgrades Comerica to Neutral from Buy as rate hikes wane
Goldman Sachs analyst Ryan Nash downgraded Comerica (CMA) to Neutral from Buy and lowered his price target for the shares to $84 from $89. While loan growth has begun to improve from the lows, a lack of additional interest rate hikes, along with more exposure to consumer deposits continuing to re-price higher, likely means that the company's margins will begin to compress beyond Q1, Nash tells investors in a research note. He believes this will "pressure" consensus estimates. In the Regional Banks space, the analyst is most upbeat on Signature Bank (SBNY), Citizens Financial (CFG) and Cadence Bancorp (CADE) into Q1. He's less optimistic on First Horizon (FHN) and Huntington Bancshares (HBAN).
01/09/19
SBSH
01/09/19
UPGRADE
Target $37
SBSH
Buy
Citizens Financial upgraded to Buy from Neutral at Citi
Citi analyst Keith Horowitz upgraded Citizens Financial Group to Buy with a $37 price target. The analyst believes the company offers one of the most attractive tactical buying opportunities given its current "dislocated" valuation.
01/07/19
GSCO
01/07/19
UPGRADE
Target $40
GSCO
Conviction Buy
Citizens Financial upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Ryan Nash added Citizens Financial to his firm's Americas Conviction List while keeping a Buy rating on the name. The current valuation presents a "compelling entry point" following the recent selloff, Nash tells investors in a research note. He believes the market appears to be pricing in an 80% probability of a moderate recession. However, if this doesn't happen over the next 12-18 months, the shares should advance 25%-plus, says the analyst. Nash lowered his price target for Citizens Financial to $40 from $44.
03/12/19
BMOC
03/12/19
INITIATION
Target $17
BMOC
Outperform
Regions Financial initiated with an Outperform at BMO Capital
BMO Capital analyst Lana Chan started Regions Financial (RF) with an Outperform rating and $17 price target. The analyst left the company's recent investor day "impressed" with its three-year strategy to improve profitability through further efficiency gains and with "seemingly moderate" credit risk. This would "upshift" Regions' profitability and should improve its "historically discounted" valuation to peers, Chan tells investors in a research note. The analyst's order of preference among Outperform-rated regional banks are BB&T (BBT), Regions, and Citizens Financial (CFG).
MTZ MasTec
$48.38

0.65 (1.36%)

11/09/18
BARD
11/09/18
DOWNGRADE
Target $54
BARD
Neutral
MasTec downgraded to Neutral at Baird
As reported previously, Baird analyst Andrew Wittmann downgraded MasTec to Neutral from Outperform. The analyst feel the potential catalyst have played out and even though a lot of good things are happening they appear to be well known. Wittmann feels the risk/reward is now better balanced and he raised his price target to $54 from $52 on MasTec shares.
12/19/18
STFL
12/19/18
NO CHANGE
Target $61
STFL
Buy
MasTec added to Select List on 'extremely strong' ouotlok at Stifel
Stifel analyst Noelle Dilts added MasTec to her firm's Select List saying she sees an "extremely strong" outlook for 2019 as activity in the core pipeline and telecom markets accelerates, driving high levels of utilization. The analyst views MasTec's "soft" guidance for flattish revenue year-over-year in oil and gas as too low, and sees opportunity for margin outperformance. Dilts sees a "good set up for outperformance relative to estimates in 2019 and catalysts ahead." The analyst trimmed her price target for MasTec to $61 from $63 and keeps a Buy rating on the shares.
02/04/19
DADA
02/04/19
NO CHANGE
Target $57
DADA
Buy
MasTec price target lowered to $57 from $62 at DA Davidson
DA Davidson analyst Brent Thielman lowered his price target on MasTec to $57 after his meetings with its management and institutional investors last week. The analyst is lowering his 2019/2020 estimates to reflect the lower first half contributions and more conservative growth expectations into 2020, but keeps his Buy rating longer term, citing the positive discussions about the company's end markets and expectations of a ramp in telco/5G spending.
05/06/19
KEYB
05/06/19
NO CHANGE
Target $65
KEYB
Overweight
MasTec price target raised to $65 from $60 at KeyBanc
KeyBanc analyst Tahira Afzal raised his price target for MasTec to $65 from $60 as increased 2019 guidance shows confidence in key end markets, including reinforcement of an expected second half of the year ramp in telecom revenues and ongoing resilience in pipe activity. Additionally, he sees incremental visibility in 2020 for segments beyond Telecom and Pipelines, leading to improved diversity and quality in revenue base and reduced client concentration risk. The analyst reiterates an Overweight rating on the shares.
USB U.S. Bancorp
$51.06

0.25 (0.49%)

02/08/19
02/08/19
NO CHANGE

Odeon's Bove says buy SunTrust, Midwest banks after deal announcement
Odeon analyst Dick Bove recommends investors buy shares of SunTrust (STI) following the company's announcement of an agreement to merge with BB&T (BBT), stating that the deal is expected to be accretive by 2021, but likely to be dilutive before this time. He also thinks investors should consider buying a group of Midwestern banks, as the deal puts "significant pressure" on those banks to merge. Banks such as Fifth Third (FITB) and KeyCorp (KEY) "need to join forces," while PNC (PNC) and U.S. Bancorp (USB) "need to buy more scale," Bove stated in his research note.
01/28/19
BARD
01/28/19
DOWNGRADE
Target $55
BARD
U.S. Bancorp downgraded to Neutral following recent rally at Baird
As reported previously, Baird analyst David George downgraded U.S. Bancorp to Neutral from Outperform. The analyst cited its recent rally and outperformance of the banking index relative to the market. He said the risk/reward is now more balanced and noted that the stock trades at a slight premium to peers. George maintained his $55 price target on U.S. Bancorp shares.
01/28/19
01/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Autohome (ATHM) downgraded to Underweight from Neutral at JPMorgan with analyst Binbin Ding saying he expects the company to see weakened pricing power amid a "challenging" market environment. 2. Vale (VALE) downgraded to Hold from Buy at HSBC and Jefferies, to Neutral from Outperform at Macquarie, and to Market Perform from Outperform at BMO Capital. 3. Amgen (AMGN) downgraded to In Line from Outperform at Evercore ISI with analyst Umer Raffat citing increased biosimilar competition and an imminent court decision on Enbrel patents with Sandoz. 4. Dynagas LNG (DLNG) downgraded to Neutral from Buy at B. Riley FBR with analyst Liam Burke saying the company "significantly" reduced its cash distribution in order to strengthen its balance sheet. 5. SunTrust (STI) and U.S. Bancorp (USB) were downgraded to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
NDAQ Nasdaq
$91.10

0.2 (0.22%)

02/06/19
ARGS
02/06/19
INITIATION
Target $97
ARGS
Buy
Nasdaq initiated with a Buy at Argus
Argus initiated Nasdaq with a Buy and $97 price target.
02/06/19
02/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nasdaq (NDAQ) initiated with a Buy at Argus. 2. Marinus Pharmaceuticals (MRNS) initiated with an Outperform at Leerink. 3. PolyOne (POL) initiated with a Buy at Buckingham. 4. Marathon Petroleum (MPC) initiated with an Outperform at Macquarie. 5. CymaBay (CBAY) initiated with a Neutral at B. Riley FBR.This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/19
ARGS
02/06/19
INITIATION
Target $97
ARGS
Buy
Nasdaq initiated with a Buy at Argus
As noted earlier, Argus analyst Kevin Heal initiated Nasdaq with a Buy rating and a price target of $97, citing the company's latest Q4 results that showed an 11% growth in organic revenue and a 21% growth in EPS driven by "equity market volatility and gains in its nontrading businesses." The analyst expects Nasdaq to benefit from the "secular trends in its core data and listings business, including increased demand for real-time data and analytics, the growing popularity of passive index investing, and the need for greater price transparency." Heal further expects investor focus to remain on the company's "strong trading volumes".
11/28/18
ATLE
11/28/18
INITIATION
Target $105
ATLE
Overweight
Nasdaq initiated with an Overweight at Atlantic Equities
Atlantic Equities analyst Nadja Heini initiated Nasdaq with an Overweight and $105 price target.
SPGI S&P Global
$211.77

3.09 (1.48%)

02/08/19
UBSW
02/08/19
DOWNGRADE
Target $205
UBSW
Neutral
S&P Global downgraded to Neutral from Buy at UBS
UBS analyst Alex Kramm downgraded S&P Global to Neutral while raising his price target for the shares to $205 from $200. The company's outlook "remains highly uncertain for now," Kramm tells investors in a research note.
01/11/19
ATLE
01/11/19
UPGRADE
Target $210
ATLE
Overweight
Atlantic sees better entry point into S&P Global, upgrades to Overweight
As previously reported before the open, Atlantic Equities analyst John Heagerty upgraded S&P Global (SPGI) to Overweight from Neutral, stating that the 20% decline in the shares since July has provided a better entry point into the stock. He lowered his EPS forecasts for both S&P and Moody's (MCO) to account for the fact that corporate debt issuance was "very weak" in Q4. However, he also noted that high yield spreads have narrowed quickly since the beginning of the year, which he believes should provide a steadier platform for issuance in 2019. Also, debt refinancing requirements, particularly for high yield issuers, continue to increase, noted Heagerty, who has a $210 price target on S&P shares.
01/11/19
ATLE
01/11/19
UPGRADE
ATLE
Overweight
S&P Global upgraded to Overweight from Neutral at Atlantic Equities
RF Regions Financial
$14.54

0.2 (1.39%)

04/23/19
MACQ
04/23/19
DOWNGRADE
MACQ
Underperform
Regions Financial downgraded to Underperform from Neutral at Macquarie
03/25/19
03/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Regions Financial (RF) upgraded to Buy from Hold at Sandler O'Neill with analyst Stephen Scouten saying he does not believe there is more than 3%-5% of potential downside to 2021 numbers if there are not a couple of Fed rate reductions in 2020. 2. TAL Education (TAL) and New Oriental Education (EDU) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. First Bancorp (FBNC) and MidSouth Bancorp (MSL) upgraded to Buy from Hold at Sandler O'Neill. 4. Lexicon (LXRX) upgraded to Hold from Sell at Gabelli with analyst Kevin Kedra citing the company's announcement that the FDA had issued a complete response letter for sotagliflozin to treat type 1 diabetes, consistent with his expectations. 5. Hibbett Sports (HIBB) upgraded to Positive from Neutral at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
SDLR
03/25/19
UPGRADE
Target $17
SDLR
Buy
Regions Financial upgraded to Buy after four-day Fed selloff at Sandler O'Neill
As previously reported, Sandler O'Neill analyst Stephen Scouten upgraded Regions Financial to Buy from Hold with the stock having declined over 16% since Tuesday's Fed commentary, which he views as overdone. Scouten does not believe there is more than 3%-5% of potential downside to 2021 numbers if there are not a couple of Fed rate reductions in 2020. He also continues to think Regions can slowly grow loans, maintain the NIM in the current range and deliver positive operating leverage in the coming years, he tells investors. He has a $17 price target on Regions shares.
03/29/19
NOMU
03/29/19
UPGRADE
Target $14
NOMU
Neutral
Regions Financial upgraded to Neutral from Reduce at Nomura Instinet
Nomura Instinet analyst Bill Carcache upgraded Regions Financial to Neutral from Reduce with an unchanged price target of $14. The analyst believes the shares are near a fair valuation.
MTB M&T Bank
$162.66

1.03 (0.64%)

04/16/19
WEDB
04/16/19
NO CHANGE
Target $155
WEDB
Neutral
M&T Bank price target raised to $155 from $150 at Wedbush
Wedbush analyst Peter Winter raised his price target for M&T Bank to $155 from $150 following quarterly results. The analyst reiterates a Neutral rating on the shares.
02/21/19
BARD
02/21/19
DOWNGRADE
BARD
Neutral
M&T Bank downgraded to Neutral from Outperform at Baird
02/21/19
BARD
02/21/19
DOWNGRADE
Target $175
BARD
Neutral
Baird downgrades M&T Bank to Neutral, says risk/reward less compelling
As reported previously, Baird analyst David George downgraded M&T Bank to Neutral from Outperform. The analyst said the risk/reward is less compelling following the stock's recent rally. He also believes the bank's opportunity for efficiency improvement is more limited versus peers and loan growth likely remains muted. George maintained his $175 price target on M&T Bank shares.
01/09/19
UBSW
01/09/19
UPGRADE
Target $157
UBSW
Neutral
M&T Bank upgraded to Neutral from Sell at UBS
UBS analyst Saul Martinez upgraded M&T Bank to Neural while lowering his price target for the shares to $157 from $171. The stock's "ample" valuation de-rating has brought a balanced risk/reward profile, Martinez tells investors in a research note.
BK BNY Mellon
$47.00

-0.16 (-0.34%)

01/08/19
JEFF
01/08/19
DOWNGRADE
Target $91
JEFF
Hold
Jefferies cuts trust bank estimates, downgrades Northern Trust to Hold
Jefferies analyst Ken Usdin downgraded Northern Trust (NTRS) to Hold from Buy and lowered his price target for the shares to $91 from $121. The sharp Q4 decline in market levels weighs on trust banks' revenue estimates, Usdin tells investors in a research note. He downgraded Northern Trust with his 2020 earnings estimate now 7% below consensus. Trust bank valuations remain below historical averages, but slower organic growth and "less macro help" are challenges, says the analyst. He also lowered his price target for Hold-rated BNY Mellon (BK) to $50 and Hold-rated State Street (STT) to $70.
01/09/19
SBSH
01/09/19
DOWNGRADE
Target $52
SBSH
Neutral
BNY Mellon downgraded to Neutral from Buy at Citi
Citi analyst Keith Horowitz downgraded BNY Mellon to Neutral with a $52 price target. The analyst believes the company's valuation relative to peers has gotten full and says he cannot justify a strong case for 15% plus upside from current levels. He views BK as fairly valued at current prices.
04/18/19
RBCM
04/18/19
NO CHANGE
Target $52
RBCM
Sector Perform
BNY Mellon price target lowered to $52 from $58 at RBC Capital
RBC Capital analyst Gerard Cassidy lowered his price target on BNY Mellon to $52 and kept his Sector Perform rating, saying the company hit an "air pocket" in Q1 as revenues underperformed expectations due to pricing pressure and negative core business trends. The analyst notes that BNY Mellon is "focused on optimizing profitability through organic growth" but the stock may continued trading at the lower end of its historical multiple range until there is an improvement in pricing, a more benign outlook for interest rates, and more consistent positive operating leverage.
10/19/18
10/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Las Vegas Sands (LVS) downgraded to Buy from Conviction Buy at Goldman Sachs. 2. eBay (EBAY) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying PayPal's (PYPL) earnings release last night suggested weak eBay gross merchandise volume trends in Q3. 3. Ford (F) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Adam Jonas saying he now believes the market needs more evidence of success before embracing the Ford restructuring story. 4. BNY Mellon (BK) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying while the company beat estimates this quarter, several line items were weaker than expectations. 5. Harley-Davidson (HOG) downgraded to Market Perform from Outperform at BMO Capital with analyst Gerrick Johnson saying his previously expected catalysts for sales and earnings did not materialize. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CGC Canopy Growth
$45.28

1.555 (3.56%)

04/25/19
DESJ
04/25/19
INITIATION
DESJ
Buy
Desjardins initiates HEXO Corp, Canopy Growth, Aurora Cannabis with a Buy
Desjardins analyst John Chu initiated HEXO Corp (HEXO), Canopy Growth (CGC), and Aurora Cannabis (ACB) with a Buy rating and respective price targets of C$14, C$74, and C$16.50 as part of a broad research note, saying the "hype" around legalization of adult-use cannabis in Canada remains strong in spite of "underwhelming" early months of sales. The analyst attributes the challenges to ramp-up, logistical and distribution issues, but expects investors to consider the opportunity as a "global" one. Chu believes that "major" consumer packaged goods companies like Constellation (STZ), InBev (BUD), and Altria (MO), as well as retailers like Walgreens (WBA), CVS (CVS), and Rite Aid (RAD) should "help push cannabis and hemp into the mainstream."
04/25/19
DESJ
04/25/19
INITIATION
DESJ
Buy
Canopy Growth initiated with a Buy at Desjardins
05/13/19
AGPP
05/13/19
INITIATION
AGPP
Buy
Canopy Growth initiated with a Buy at Alliance Global Partners
Alliance Global Partners analyst Aaron Grey initiated Canopy Growth with a Buy rating and C$75 price target, citing his view that the company can become the "global leader in cannabis" following its game-changing acquisition agreement with Acreage Holdings (ACRGF) to give it access to the world's largest cannabis market in the U.S. Though he does not foresee Canopy being profitable until FY21, Grey noted that he does expect the company to be profitable in the Canadian cannabis market as it continues with its international expansion.
04/22/19
BNCH
04/22/19
NO CHANGE
BNCH
Buy
Canopy Growth acquisition provides path to U.S. market, says Benchmark
The acquisition of Acreage Holdings provides a path for Canopy Growth to enter the U.S. market upon eventual federal legalization of cannabis production and sale, Benchmark analyst Mike Hickey tells investors in a research note. The analyst estimates the U.S. cannabis market is 10 times the Canadian market. He keeps a Buy rating on Canopy Growth shares with a C$100 price target. However, cannabis sales data from Canada Health suggests a slow start to Q1, Hickey points out. As such, he expects the company to report fiscal Q4 sales of C$93M, below the consensus of C$98M. Canopy Growth in early trading is up 2% to $45.52 after GMP Securities upgraded the shares to Buy.

TODAY'S FREE FLY STORIES

INTU

Intuit

$241.77

-5.75 (-2.32%)

12:50
05/23/19
05/23
12:50
05/23/19
12:50
Hot Stocks
Senators ask Intuit about reports of misleading taxpayers on free options »

Senator Elizabeth Warren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

INTU

Intuit

$241.84

-5.68 (-2.29%)

12:47
05/23/19
05/23
12:47
05/23/19
12:47
Periodicals
TurboTax's 'discount' tricks military into paying to file taxes, ProPublica says »

Intuit, the maker of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

12:45
05/23/19
05/23
12:45
05/23/19
12:45
General news
Breaking General news story  »

San Francisco Federal…

12:45
05/23/19
05/23
12:45
05/23/19
12:45
General news
Breaking General news story  »

Richmond Federal Reserve…

12:45
05/23/19
05/23
12:45
05/23/19
12:45
General news
Breaking General news story  »

Dallas Federal Reserve…

12:45
05/23/19
05/23
12:45
05/23/19
12:45
General news
Breaking General news story  »

Atlanta Federal Reserve…

BCYC

Bicycle Therapeutics

$12.15

(0.00%)

12:44
05/23/19
05/23
12:44
05/23/19
12:44
Syndicate
Bicycle Therapeutics slides after opening at $13.37 »

Bicycle Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BDX

Becton Dickinson

$232.04

-3.72 (-1.58%)

12:44
05/23/19
05/23
12:44
05/23/19
12:44
Hot Stocks
Becton Dickinson VP Samrat Khichi sells almost $3.8M in company stock »

Becton Dickinson VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$42.50

-1.06 (-2.43%)

12:40
05/23/19
05/23
12:40
05/23/19
12:40
Options
Schwab puts active as shares shed 2.6% »

Schwab puts active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTOO

T2 Biosystems

$1.91

-0.65 (-25.39%)

12:39
05/23/19
05/23
12:39
05/23/19
12:39
Recommendations
T2 Biosystems analyst commentary  »

T2 Biosystems selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

HPQ

HP Inc.

$19.01

-0.28 (-1.45%)

, CSCO

Cisco

$54.13

-1.56 (-2.80%)

12:37
05/23/19
05/23
12:37
05/23/19
12:37
Earnings
Fly Intel: What to watch in HP Inc.'s earnings report »

HP Inc. (HPQ) is…

HPQ

HP Inc.

$19.01

-0.28 (-1.45%)

CSCO

Cisco

$54.13

-1.56 (-2.80%)

JNPR

Juniper

$25.33

-0.54 (-2.09%)

CIEN

Ciena

$34.97

-0.29 (-0.82%)

FFIV

F5 Networks

$137.43

-2.9 (-2.07%)

NOK

Nokia

$4.98

-0.14 (-2.73%)

MSFT

Microsoft

$124.85

-2.82 (-2.21%)

AAPL

Apple

$178.43

-4.18 (-2.29%)

DELL

Dell Technologies

$65.75

-3.26 (-4.72%)

LNVGY

Lenovo

$0.00

(0.00%)

GOOG

Alphabet

$1,129.61

-20.89 (-1.82%)

GOOGL

Alphabet Class A

$1,133.98

-19.13 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 06

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 11

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 24

    Jul

  • 06

    Aug

  • 14

    Aug

  • 27

    Oct

TTWO

Take-Two

$103.79

-0.49 (-0.47%)

, EA

Electronic Arts

$92.40

-1.72 (-1.83%)

12:36
05/23/19
05/23
12:36
05/23/19
12:36
Periodicals
Bill to ban video game loot boxes gains bipartisan Senate support, Polygon says »

Democratic senators…

TTWO

Take-Two

$103.79

-0.49 (-0.47%)

EA

Electronic Arts

$92.40

-1.72 (-1.83%)

ATVI

Activision Blizzard

$42.30

-0.61 (-1.42%)

TCEHY

Tencent

$0.00

(0.00%)

UBSFY

Ubisoft

$0.00

(0.00%)

NTDOY

Nintendo

$0.00

(0.00%)

MSFT

Microsoft

$124.84

-2.83 (-2.22%)

SNE

Sony

$48.42

-2.07 (-4.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 06

    Aug

  • 13

    Nov

TSLA

Tesla

$194.73

3.34 (1.75%)

12:34
05/23/19
05/23
12:34
05/23/19
12:34
Hot Stocks
Tesla has no immediate plans to raise money, Charles Gasparino tweets »

Charles Gasparino of Fox…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

TTOO

T2 Biosystems

$1.92

-0.64 (-25.00%)

12:34
05/23/19
05/23
12:34
05/23/19
12:34
Recommendations
T2 Biosystems analyst commentary  »

T2 Biosystems shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

XLF

Financial Select Sector

$26.60

-0.4 (-1.48%)

12:30
05/23/19
05/23
12:30
05/23/19
12:30
Options
Hedging activity in SPDR Healthcare Fund »

Hedging activity in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUX

McEwen Mining

$1.30

0.045 (3.60%)

12:25
05/23/19
05/23
12:25
05/23/19
12:25
Conference/Events
McEwen Mining to hold a company meeting »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$178.95

-3.66 (-2.00%)

12:24
05/23/19
05/23
12:24
05/23/19
12:24
Periodicals
Samsung, Apple reportedly in talks over OLED displays, MacRumors reports »

Samsung (SSNLF) is in…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$178.95

-3.66 (-2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

VIPS

Vipshop

$7.44

-0.31 (-4.00%)

12:20
05/23/19
05/23
12:20
05/23/19
12:20
Upgrade
Vipshop rating change at CLSA »

Vipshop upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

MCD

McDonald's

$198.36

-1.82 (-0.91%)

, QSR

Restaurant Brands

$69.14

0.43 (0.63%)

12:20
05/23/19
05/23
12:20
05/23/19
12:20
Periodicals
McDonald's not planning to add plant-based burger to menu, CNBC reports »

McDonald's (MCD)…

MCD

McDonald's

$198.36

-1.82 (-0.91%)

QSR

Restaurant Brands

$69.14

0.43 (0.63%)

BYND

Beyond Meat

$81.73

4.23 (5.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 06

    Jun

HAL

Halliburton

$23.23

-1.29 (-5.26%)

12:20
05/23/19
05/23
12:20
05/23/19
12:20
Options
Hefty option play in Halliburton as shares shed nearly 6% »

Hefty option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 13

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
05/23/19
05/23
12:17
05/23/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
05/23/19
05/23
12:16
05/23/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$136.16

-3.38 (-2.42%)

, MU

Micron

$33.30

-1.43 (-4.12%)

12:15
05/23/19
05/23
12:15
05/23/19
12:15
Periodicals
Hedge-fund manager David Tepper may be planning to return money, WSJ says »

According to a Wall…

AGN

Allergan

$136.16

-3.38 (-2.42%)

MU

Micron

$33.30

-1.43 (-4.12%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.31

-4.31 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 25

    Jun

VIPS

Vipshop

$7.41

-0.34 (-4.39%)

12:15
05/23/19
05/23
12:15
05/23/19
12:15
Upgrade
Vipshop rating change at Credit Suisse »

Vipshop upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CTL

CenturyLink

$9.82

-0.135 (-1.36%)

12:15
05/23/19
05/23
12:15
05/23/19
12:15
Options
CenturyLink put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.